ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 1791

Determining the Effect of CD14 Deficiency on Osteoblastogenesis and Subchondral Bone Remodeling In Mice

(1780–1808) Osteoarthritis & Joint Biology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 1967

Developing an Algorithm to Quantify Dermatomyositis-Associated Calcinosis Using Infrared Imaging

(1936–1971) Imaging of Rheumatic Diseases Poster

10:30AM-12:30PM: Abstract Number: 1888

Developing Machine Learning Algorithm in Electronic Health Record to Accurately Identify Psoriasis Patients

(1877–1913) Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2173

Developing Musculoskeletal Ultrasound Clinical Electives: Bridging the Basic Sciences and Clinical Application in Undergraduate Medical Education

(2159–2194) Professional Education Poster

10:30AM-12:30PM: Abstract Number: 2186

Developing Rheumatology Specific Anki Electronic Flashcards for Teaching Preclinical Students United States Medical Licensing Examination Board Relevant Topics 

(2159–2194) Professional Education Poster

10:30AM-12:30PM: Abstract Number: 2334

Development and validation analysis of a Corrected Axial Spondyloarthritis Metrology Index

(2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2332

Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints: DAPSA44

(2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2125

Development and Validation of Minimal Clinically Important Difference for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach

(2124–2158) Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2550

Development of a ‘Training Toolkit’ to Support Advanced Practice Providers (APPs) Entry into a Rheumatology Musculoskeletal Ultrasound Subspecialty Clinic

(2547–2566) ARP Posters I

10:30AM-12:30PM: Abstract Number: 2114

Development of a Fracture Prediction Model for Patients Aging with HIV

(2106–2123) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2027

Development of a multi-disease panel for autoimmune diseases

(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2469

Development of Consensus Statements on Glucocorticoid Use in Systemic Lupus Erythematosus

(2437–2469) Systemic Lupus Erythematosus – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2541

Development of Severity Classification Criteria for Introduction of Infliximab for Chronic Pogressive Neuro-Behçet’s Disease

(2524–2546) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

10:30AM-12:30PM: Abstract Number: 1927

Development of the PREVAIL model of care: Optimizing feasibility and acceptability for trial implementation

(1914–1935) Health Services Research Poster III

10:30AM-12:30PM: Abstract Number: 2191

Development, Validation and Performance of a Questionnaire for Assessing the Knowledge Base of Primary Care Physicians About Management of Rheumatoid Arthritis and Impact of an Information Course

(2159–2194) Professional Education Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].